← Eichor
Study identifier: NCT07580196 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

Condition: Prostate Cancer  ·  Sponsor: University of Turin, Italy

PhaseNA
Planned participants820
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

BALANCE is a multicenter, prospective, randomized controlled trial enrolling men with unilateral high-risk localized prostate cancer identified by prostate biopsy, multiparametric MRI, and PSMA PET imaging. Eligible patients scheduled for robot-assisted radical prostatectomy will be randomized in a 1:1 ratio to undergo either unilateral extended pelvic lymph node dissection or bilateral extended pelvic lymph node dissection. Pelvic lymph node dissection is commonly performed in high-risk prostate cancer for staging purposes, but its therapeutic benefit remains uncertain and the procedure may increase operative time, costs, and postoperative morbidity. Modern imaging techniques may improve the identification of patients with predominantly unilateral disease and support a more selective surgical approach. The co-primary objectives are to compare 3-year biochemical recurrence-free survival and early postoperative PSA persistence between the two surgical strategies. Secondary objectives include comparison of perioperative complications, operative time, blood loss, length of hospital stay, quality of life, long-term oncologic outcomes, and costs. This study is designed to determine whether unilateral extended pelvic lymph node dissection can reduce surgical morbidity while preserving oncologic outcomes in appropriately selected patients with high-risk prostate cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Chiara Fiameni  ·  +39 011 633 6591  ·  chiara.fiameni@unito.it

Alessandro Marquis, MD  ·  +39 011 633 6591  ·  alessandro.marquis@unito.it

Always discuss trial participation with your own doctor first.

Locations (14)

Humanitas Clinical and Research Centre & Humanitas UniversityRozzano, Milano, ItalyNot Yet Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola-Malpighi & University of BolognaBologna, ItalyNot Yet Recruiting
Università degli Studi di Firenze / AOU CareggiFlorence, ItalyNot Yet Recruiting
Università degli Studi di Foggia / AO Ospedali Riuniti di FoggiaFoggia, ItalyNot Yet Recruiting
IRCCS Ospedale Policlinico San Martino & University of GenoaGenova, ItalyNot Yet Recruiting
IEO, Istituto Europeo di OncologiaMilan, ItalyNot Yet Recruiting
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyNot Yet Recruiting
Università degli Studi di Modena / AOU ModenaModena, ItalyNot Yet Recruiting
Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale"Naples, ItalyNot Yet Recruiting
Università Tor Vergata / Policlinico Tor VergataRoma, ItalyNot Yet Recruiting
IFO - Istituti Fisioterapici OspitalieriRoma, ItalyNot Yet Recruiting
Policlinico Universitario Gemelli IRCCS & Università Cattolica del Sacro CuoreRoma, ItalyNot Yet Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07580196